Rubius Therapeutics to Announce Third Quarter 2019 Financial Results
November 05, 2019 16:05 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces Oncology Poster Presentations at Upcoming Medical Conferences
October 17, 2019 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference
September 03, 2019 16:05 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
August 13, 2019 08:00 ET
|
Rubius Therapeutics
On Track to Report Initial Clinical Data from Phase 1b Clinical Trial of RTX-134 for Phenylketonuria by Year-End CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc....
Rubius Therapeutics to Announce Second Quarter 2019 Financial Results
August 07, 2019 16:05 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy
July 25, 2019 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs
June 05, 2019 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference
May 28, 2019 16:05 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...
Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
May 15, 2019 08:00 ET
|
Rubius Therapeutics
Enrollment for Phase 1b Trial of RTX-134 for Phenylketonuria on Track for Second Quarter 2019; Initial Clinical Data Anticipated in Second Half 2019 Company Announces Transition of President Torben...
Rubius Therapeutics to Announce First Quarter 2019 Financial Results
May 06, 2019 16:05 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them...